BioSpace News Archive

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the opening of nine additional sites for recruitment into its pivotal NAV3-33 Phase 3 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA).

DermistatTM, one of the latest wound healing innovations by BioLab Sciences, a regenerative biotechnology company, has emerged as the go-to wound healing option for wound care specialists and podiatrists throughout the country.

Revelle Aesthetics, Inc. (Revelle) – a VC-backed Silicon Valley MedTech company – achieves an extended FDA clearance for its precision cellulite release device, Avéli™.

GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced that it has appointed Nicole Lemerond, CFA, to its Board of Directors.

4DMedical, the leading developer of functional imaging software for respiratory illness, announced successful completion of a study by Vanderbilt University Medical Center of post-deployment veterans referred by the Nashville VA.

Acadia Pharmaceuticals Inc. announced that it will participate at the following upcoming investor conferences.

GenBody America, LLC, the U.S. affiliate of GenBody, Inc., today announced that the U.S. Food and Drug Administration (FDA) has made an amendment to the emergency use authorization for the GenBody COVID-19 Ag kit, which has been updated to include prefilled individual reagent tubes for each test device.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong.

Neogen Corporation announced that it has completed the previously announced merger with 3M’s Food Safety business to create an innovative leader in the food safety sector with a comprehensive product range and a strategic focus on the category’s long-term growth opportunities.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a 30-µg booster dose of their Omicron BA.1 Bivalent COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.1 15/15 µg) has been recommended for conditional marketing authorization (cMA) by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for individuals 12 years and older.